Themis Medicare Limited has informed the Exchange about Investor Presentation
THEMISMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Themis Medicare shared its Q1 FY26 investor presentation showing a sharp downturn in performance. Consolidated revenue fell to ₹97.58 crore from ₹123 crore a year ago, while the company slipped into a loss with EBITDA of -₹10.08 crore and PAT of -₹14.22 crore, against profits of ₹29.18 crore and ₹24.68 crore respectively in Q1 FY25. Management attributed the weakness to disruption in a high-margin business caused by substandard imitation products in the market, with regulators now investigating. Positively, the API business grew 77% year-on-year, Pharma business rose 19%, and the Hospital and Trade businesses expanded 49% and 165% quarter-on-quarter. The company has laid out a 3-year roadmap targeting 35% CAGR in the Hospital business and EBITDA margins above 25%, with plans to expand into CIS, Latin America, and GCC markets in Phase I and enter regulated EU/US markets in Phase II.
The Q1 results are likely to weigh on the stock given the swing to losses and the imitation-related disruption. However, management's forward-looking targets, API recovery, and growth in hospital and trade segments could provide some cushion, making this a mixed read for investors.